EUVIMEDEUVIMED entdecken
Klinische Studie (Phase II)

Toxicity and Patient-Reported Quality-of-Life Outcomes After Prostate Stereotactic Body Radiation Therapy With Focal Boost to Magnetic Resonance Imaging-Identified Prostate Cancer Lesions: Results of a Phase 2 Trial

Brett A Morris, Emma E Holmes, Nicholas J Anger, Gregory Cooley, Jessica M Schuster, Newton Hurst, Andrew M Baschnagel, Michael F Bassetti, Grace C Blitzer, Richard J Chappell, Robert A Bayliss, Zachary S Morris und 2 weitere

International Journal of Radiation Oncology*Biology*Physics · 2023

DOI: 10.1016/j.ijrobp.2023.05.004 ↗

Kurz gefasst

Klinische Studie (Phase II) in der Zeitschrift International Journal of Radiation Oncology*Biology*Physics, 2023. Verfasst von Brett A Morris und 13 weiteren Autor:innen. Beteiligte Einrichtung: Departments of Human Oncology. Electronic address: bmorris@uwhealth.org. Hauptthemen laut MEDLINE: Radiosurgery, Prostatic Neoplasms, Gastrointestinal Diseases. Die Arbeit wurde bisher 16-mal zitiert (Crossref) und nennt 41 Literaturangaben. Gefördert von: NCI NIH HHS, National Institutes of Health, University of Wisconsin Carbone Cancer Center.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

PURPOSE: In this prospective phase 2 trial, we investigated the toxicity and patient-reported quality-of-life outcomes in patients treated with stereotactic body radiation therapy (SBRT) to the prostate gland and a simultaneous focal boost to magnetic resonance imaging (MRI)-identified intraprostatic lesions while also de-escalating dose to the adjacent organs at risk. METHODS AND MATERIALS: Eligible patients included low- or intermediate-risk prostate cancer (Gleason score ≤7, prostate specific antigen ≤20, T stage ≤2b). SBRT was prescribed to 40 Gy in 5 fractions delivered every other day to the prostate, with any areas of high disease burden (MRI-identified prostate imaging reporting and data system 4 or 5 lesions) simultaneously escalated to 42.5 to 45 Gy and areas overlapping organs at risk (within 2 mm of urethra, rectum, and bladder) constrained to 36.25 Gy (n = 100). Patients without a pretreatment MRI or without MRI-identified lesions were treated to dose of 37.5 Gy with no focal boost (n = 14). RESULTS: From 2015 to 2022, a total of 114 patients were enrolled with a median follow-up of 42 months. No acute or late grade 3+ gastrointestinal (GI) toxicity was observed. One patient developed late grade 3 genitourinary (GU) toxicity at 16 months. In patients treated with focal boost (n = 100), acute grade 2 GU and GI toxicity was seen in 38% and 4% of patients, respectively. Cumulative late grade 2+ GU and GI toxicities at 24 months were 13% and 5% respectively. Patient-reported outcomes showed no significant long-term change from baseline in urinary, bowel, hormonal, or sexual quality-of-life scores after treatment. CONCLUSIONS: SBRT to a dose of 40 Gy to the prostate gland with a simultaneous focal boost up to 45 Gy is well tolerated with similar rates of acute and late grade 2+ GI and GU toxicity as seen in other SBRT regimens without intraprostatic boost. Moreover, no significant long-term changes were seen in patient-reported urinary, bowel, or sexual outcomes from pretreatment baseline.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

RadiosurgeryProstatic NeoplasmsGastrointestinal DiseasesMaleHumansProstateProspective StudiesQuality of LifeMagnetic Resonance ImagingPatient Reported Outcome Measures

Autor:innen und Institutionen

  • Departments of Human Oncology. Electronic address: bmorris@uwhealth.org.
  • Biostatistics & Medical Informatics, University of Wisconsin School of Medicine and Public Health, Madison, Wisconsin.
  • Departments of Human Oncology.

Förderung

  • NCI NIH HHS
  • National Institutes of Health
  • University of Wisconsin Carbone Cancer Center

Zitieren

APA

Morris, B. A., Holmes, E. E., Anger, N. J., Cooley, G., Schuster, J. M., Hurst, N., Baschnagel, A. M., Bassetti, M. F., Blitzer, G. C., Chappell, R. J., Bayliss, R. A., Morris, Z. S., Ritter, M. A., & Floberg, J. M. (2023). Toxicity and Patient-Reported Quality-of-Life Outcomes After Prostate Stereotactic Body Radiation Therapy With Focal Boost to Magnetic Resonance Imaging-Identified Prostate Cancer Lesions: Results of a Phase 2 Trial. International Journal of Radiation Oncology*Biology*Physics. https://doi.org/10.1016/j.ijrobp.2023.05.004

Vancouver

Morris BA, Holmes EE, Anger NJ, Cooley G, Schuster JM, Hurst N, et al. Toxicity and Patient-Reported Quality-of-Life Outcomes After Prostate Stereotactic Body Radiation Therapy With Focal Boost to Magnetic Resonance Imaging-Identified Prostate Cancer Lesions: Results of a Phase 2 Trial. International Journal of Radiation Oncology*Biology*Physics. 2023. doi:10.1016/j.ijrobp.2023.05.004

BibTeX
@article{Morris2023,
  author = {Morris, Brett A and Holmes, Emma E and Anger, Nicholas J and Cooley, Gregory and Schuster, Jessica M and Hurst, Newton and Baschnagel, Andrew M and Bassetti, Michael F and Blitzer, Grace C and Chappell, Richard J and Bayliss, Robert A and Morris, Zachary S and Ritter, Mark A and Floberg, John M},
  title = {Toxicity and Patient-Reported Quality-of-Life Outcomes After Prostate Stereotactic Body Radiation Therapy With Focal Boost to Magnetic Resonance Imaging-Identified Prostate Cancer Lesions: Results of a Phase 2 Trial},
  journal = {International Journal of Radiation Oncology*Biology*Physics},
  year = {2023},
  doi = {10.1016/j.ijrobp.2023.05.004}
}
Kostenlos starten →